A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases

Gastric Cancer

Volumn 16, Issue 3, 2013, Pages 411-419

  Catalano, Vincenzo ^a   Bisonni, Renato ^b   Graziano, Francesco ^a   Giordani, Paolo ^a   Alessandroni, Paolo ^a   Baldelli, Anna Maria ^a   Casadei, Virginia ^a   Rossi, David ^a   Fedeli, Stefano Luzi ^a   D'Emidio, Silvia ^a   Giustini, Lucio ^b   Fiorentini, Giammaria ^a  

^a Azienda Ospedaliera Ospedali Riuniti Marche Nord   (Italy)

^b Ospedale di Fermo   (Italy)

Author keywords

Elderly; Metastatic gastric cancer; Oxaliplatin; Palliative chemotherapy

Indexed keywords

ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN;

AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHMA; BRAIN INFARCTION; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EMPHYSEMA; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEPATITIS C; HUMAN; HYPERTENSION; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; KIDNEY POLYCYSTIC DISEASE; LIVER CIRRHOSIS; MALE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OBESITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHEUMATOID ARTHRITIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULCERATIVE COLITIS; VALVULAR HEART DISEASE; VOMITING;

EID: 84880788958     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-012-0204-z     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127-64.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
5. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626-31.
6. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute: Bethesda. http://seer.cancer.gov/csr/1975-2004/ based on November 2006 SEER data submission, 2007.
7. Al Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-42.
8. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-8.
9. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658-63.
10. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer. 2004;91:453-8.
11. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92:1644-9.
12. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer. 2005;93:190-4.
13. Choi IS, Oh D-Y, Kim B-S, Lee K-W, Kim JH, Lee J-S. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat. 2007;39:99-103.
14. Nardi M, Azzarello D, Maisano R, Del Medico P, Giannicola R, Raffaele M, et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother. 2007;19:85-9.
15. Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol. 2008;31:259-63.
16. Zhao JG, Qiu F, Xiong JP, Zhang L, Xiang XJ, Yu F, et al. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anticancer Drugs. 2009;20:281-6.
17. Al-Batran S, Homann N, Hartmann JT, Moehler MH, Pauligk C, Probst S, et al. 5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65 ± trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010;28(15 suppl): abstract 4013.
18. Scott WK, Macera CA, Cornman CB, Sharpe PA. Functional health status as a predictor of mortality in men and women over 65. J Clin Epidemiol. 1997;50:291-6.
19. Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer. 2006;6:125.
20. Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol. 2009;27:e3-4.
21. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol. 2002;3:289-97.
22. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol. 2007;25:1832-43.
23. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383-9.
24. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112-24.
25. Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. Eur J Surg Oncol. 2010;36:709-17.
26. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;3:CD004064.
27. Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer. 2006;42:827-34.
28. Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol. 2006;29:371-5.
29. Fonck M, Brunet R, Becouarn Y, Legoux JL, Dauba J, Cany L, et al. Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study. Clin Res Hepatol Gastroenterol. 2011;35:823-30.